Featured
Who's Australia's Most Trusted (and Distrusted) pharma?
When it comes to trust and distrust two pharmas stand out, Australian research has found, with the Most Trusted company on a winning streak
Sales, Marketing & Public Relations
New tool puts KOLs on pharma's radar
Finding and validating KOLs across therapeutic areas just got a lot easier with a new AI-powered tool that does the heavy lifting for Medical Affairs teams
Regulatory & Reimbursement
PBAC unpacks pet peeves about pharma
Lifting the lid on the frustrating mismatch between what the Committee says it needs in order to make a recommendation and what sponsors dish up
Sales, Marketing & Public Relations
Lilly hit by health industry backlash
Platform sparks outrage from pharmacists and doctors claiming the 'Americanisation' of Australian healthcare, an accusation the company vehemently denies
Jobs
Featured
Trump nabs secret slice of Aussie drug prices
Documents obtained under Freedom of Information, suggest the US Government will share in the increased revenue pharmas generate by lifting drug prices outside the US
Industry & Companies
Missing data sinks Aussie Phase 3 trial
Interim analysis shuts down the Phase 3 trial of a flagship treatment after operational challenges resulted in missing data, throwing the future of the company into uncertainty
Regulatory & Reimbursement
First new drug in almost 20 years launched
CEO confirms plans to engage further with government and relevant stakeholders post launch, to assess the appropriate timing and pathway to a PBS listing
Regulatory & Reimbursement
Takeda snaps up recently vacated market
With its competitor being deregistered at the end of 2024, Takeda has stepped in with the only vaccine of its kind Australia for a disease with more than 2600 cases a year
Regulatory & Reimbursement
Hyped drug approved after 5-plus years
The TGA has finally given the greenlight to a drug that was lodged with the regulator in 2021, with the sponsor actively pursuing reimbursement via MSAC and the PBS
Featured
New office brings pharma team together
A change of headquarters to a brand new office space is planned to increase collaboration between teams
Featured
MA board voting opens: three leaders, two seats
Voting has opened to fill two vacancies on the Medicines Australia board with three leaders in the running
Featured
Pharma downsizes in Australia
This company is downsizing its office space following the latest restructuring in Australia, with an official move slated for the start of next month
Industry & Companies
Aussie staff let go as pharma put up for sale
A Sydney-based pharma is up for sale, with almost the entire workforce wiped out, following the appointment of a Voluntary Administrator
Leadership & People
Who made Australia's Most Powerful People list?
This high-flyer shot four places up the list to be named the third most powerful person in Australia this year - with PBS performance named as a reason for his success
Industry & Companies
Shares skyrocket 30% on new trial data
In one of the most competitive markets in the world, this company is looking to reinvent the space, and its latest topline trial results have impressed
Regulatory & Reimbursement
Changed global pricing sinks PBS listing
The shortest line yet between America's MFN policy and a life-saving drug not being PBS listed has been drawn, with a company decrying the PBAC's unwillingness to adapt to a changed pricing environment
Leadership & People
Global genomics boss heading to Australia
The Chief Scientific Officer for the NHS will visit Australia next month with a packed schedule including an address to the National Press Club to share lessons on genomics and precision medicine
Regulation & Legal
Half of PBS drugs can now be prescribed by pharmacists
New research shows almost 50 per cent of PBS prescriptions are for conditions covered by additional training being undertaken by prescribing pharmacists
Industry & Companies
Psychedelic medicines flying high
Three years after Australia's world-first decision to permit the prescribing of psilocybin and MDMA, the sector is booming and Big Pharma's are making a play
Regulation & Legal
Speed bump ahead for NZ fast-track?
New approvals pathway could put the country at risk of contravening an international trade agreement, according to lawyers
Latest
And again... Keytruda challenger shapes up
Another impressive trial win for Summit Therapeutics' challenger to the world's biggest drug has been branded a good omen for Big Pharmas in the same space
Regulatory & Reimbursement
Drug slated for PBS delisting gets more time
While manufacturing costs have gone up, reimbursement is less than half what it was when this drug was first listed but the PBAC still said 'No' to a price rise. Now plans to delist it from the PBS have been delayed by six months following a patient outcry
Sales, Marketing & Public Relations
Lilly goes direct for non-PBS meds
Faced with growing challenges to listing some drugs on the PBS, Lilly has launched a platform to facilitate dispensing and delivery of medications to a patient's door at more affordable prices
- Regulatory & Reimbursement Nine pharmas seek to add new drug labels
- Jobs & Workplace Senior leadership shake-up sweeps industry
- Jobs & Workplace 115 years on: First female CEO appointed
- Regulatory & Reimbursement 10 innovative drugs land on TGA review desk
- Industry & Companies Novo unveils five multi-blockbuster plan
- Regulatory & Reimbursement Copycats hit PBS bottleneck
- Regulatory & Reimbursement Chilling forecast on future PBS spending
- Industry & Companies Telix pays $3.3B to lock up the market
- Other News Novo dragged into horror DV weekend
- Regulatory & Reimbursement Early October listings climb to four
